AIImpactLab
9 impact clustersWork & marketsCognition & learningTechnical failuresPrivacySecurityEnvironmentLaw & informationSocial good & healthSystemic risk
Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

10 stories found

A patient reviews clear AI-prepared questions before meeting a surgeon, with an anxiety gauge and consultation timer both falling.
Social good & healthChina+4 clusters01

A local AI briefing cut pre-surgery anxiety and physician workload

A randomized phase II study offers a bounded example of medical AI that helped without pretending to replace the clinician. Researchers assigned 268 people newly diagnosed with prostate cancer and scheduled for radical prostatectomy to standard communication or an AI-assisted pathway. The intervention used a locally deployed large language model to prepare personalized answers to patient questions before the routine face-to-face discussion. Physicians remained responsible for the encounter and were blinded to group assignment. The AI-assisted group reported a mean post-communication GAD-7 anxiety score of 3.2, compared with 5.7 in the control group. Physician workload on the NASA-TLX scale averaged 39.9 versus 56.8, and routine communication time fell from 19.9 to 11.3 minutes. Satisfaction, emotions, and illness perceptions also improved. This is stronger evidence than a product testimonial, but it is not a general verdict on AI in medicine. The study was conducted at one cancer center, used a specific preoperative setting, measured near-term outcomes, and does not establish diagnostic accuracy, surgical outcomes, or long-term safety. The trial registry also still shows an earlier estimated enrollment of 160 and future completion dates, while the published paper reports 268 randomized participants; that record mismatch should be clarified. The design’s most important feature is the boundary: the model answered common questions in advance, responses were reviewed, and the surgeon still conducted the consent conversation. AI did not replace the relationship. It gave the relationship a better starting point.

10 min
An ordinary chest CT reveals a small illuminated esophageal lesion while an AI triage path directs the patient toward confirmatory endoscopy.
Social good & healthChina and international validation sites+4 clusters02

AI found hidden esophageal cancers in CT scans patients already had

A multicenter Nature Medicine study reports that an AI system called EAGLE can identify esophageal cancer and precancerous lesions in noncontrast chest CT scans that were not acquired specifically for the esophagus. The model was trained on 6,813 patients and validated across 12 centers in three countries involving 80,612 patients. In external cohorts totaling 11,466 people, it reached 90.0 percent sensitivity for cancer and 98.5 percent specificity, while sensitivity for precancerous lesions was lower at 52.5 percent. A calibration cohort of 35,402 patients reduced false positives by 72.7 percent while preserving sensitivity. In a prospective hospital cohort of 17,446 patients, 38 of 90 positive predictions were true positives, producing a 42.2 percent positive predictive value and 87.8 percent sensitivity for cancer. A real-world low-dose screening cohort of 10,959 people reported 99.94 percent specificity. The opportunity is unusually practical: use scans already being performed to identify people who should receive confirmatory endoscopy. But the strongest efficiency claims remain modeled. Simulations suggested triage could triple detection, reduce diagnostic time by 70.4 percent, and lower costs in seven of eight countries. Those are not randomized outcomes or evidence of reduced mortality. Most data came from China, follow-up was under two years, endoscopy adherence was limited, and broader validation is needed for different disease patterns. EAGLE may make existing imaging more valuable. It has not yet proved that population deployment improves survival or avoids harmful overdiagnosis.

10 min
A bright conversational knowledge pathway rises beside a closed clinical decision gate that remains in the same position.
Social good & healthJapan+3 clusters03

An HPV chatbot improved vaccine literacy without changing vaccination decisions

A randomized clinical trial in Japan found that an AI chatbot modestly improved HPV vaccine literacy compared with a standard government leaflet, but it did not measurably change caregivers' vaccination decisions after two weeks. The trial randomized 848 female caregivers of unvaccinated daughters aged 12 to 18. Its modified intention-to-treat analysis included 704 participants immediately and 477 at the two-week literacy follow-up. After adjustment, the chatbot group scored 0.30 points higher on a seven-point literacy scale at both time points. The decision result was different: 40.3 percent of assessed caregivers in the chatbot group and 39.6 percent in the leaflet group met the study's decision-to-vaccinate definition, with no statistically significant difference. The chatbot used GPT-4o with a Japan-specific library drawn from official and peer-reviewed material, stayed within a defined scope, and directed personal clinical questions to professionals. This is useful causal evidence for a narrow intervention, not proof that general-purpose chatbots improve health behavior. Attrition was substantial, participants were all female caregivers recruited online, most had college or university education, and follow-up was short. The clearest lesson is not that the chatbot failed. It is that knowledge and action are different outcomes. Scalable conversation may strengthen literacy, while trust, clinician relationships, access, and social context still determine what people do.

9 min
A sterile robotic wet lab connects an AI experiment planner to pipettes and culture plates while a scientist holds a physical safety interlock over one amber anomaly.
Social good & healthUnited States+4 clusters04

Anthropic builds a wet lab as it explores AI-directed biology

Anthropic has confirmed that it is establishing a wet laboratory in the San Francisco Bay Area and exploring whether Claude can direct robotic equipment with limited human intervention. The company's life-sciences leadership told Reuters that biology ultimately requires experiments in the physical world and that human oversight remains essential. Anthropic says the laboratory is not specifically a drug-discovery facility, has not disclosed its exact work, and is not running clinical trials. Its broader ambitions include tools for rare, neglected, and currently difficult-to-treat conditions, while its Model Hardware Standard is intended to help AI systems communicate with laboratory equipment. The company also acquired Coefficient Bio; Reuters reported a roughly $400 million stock price based on a source, but Anthropic confirmed the acquisition without confirming the amount. The opportunity is substantial: an AI system that can design an experiment, interpret results, and revise the next run could compress research cycles. The risk also changes when text output becomes physical action. A hallucinated protocol, contaminated sample, unsafe reagent combination, or overconfident biological inference can propagate through automation before a person notices. Governance should therefore attach to the closed loop, not only the model. Every AI-directed experiment needs bounded hardware permissions, validated protocols, chain-of-custody logs, biological screening, anomaly detection, and a human stop authority that remains effective when the system proposes the next step faster than a scientist can review it.

8 min
A transparent lung scan and clinical evidence panel pass through several hospital environments while a performance signal changes between sites.
Social good & healthEurope+2 clusters05

Explainable AI improved oncologists’ lung-cancer predictions, but external validation exposed the limits

A multi-country study in Nature Medicine evaluated explainable AI support for treatment decisions in advanced non-small-cell lung cancer. The retrospective I3LUNG cohort included 2,396 patients treated with immunotherapy-based regimens across six centers in six countries. Models using routine clinical and blood data achieved test performance up to an area under the curve of 0.77 and outperformed traditional single biomarkers and clinical scores in the independent test set. In a separate usability study, twenty oncologists reviewed one hundred cases first without and then with model predictions and SHAP-based explanations. Sensitivity for predicting disease control increased from 0.72 to 0.87, with gains in accuracy and F1 performance; overall-survival prediction improved more modestly. The paper is valuable because it reports the limits alongside the gains. External-validation performance fell to an AUC range of 0.55 to 0.72, the complete multimodal sample was small, and added imaging, pathology, and genomic data did not produce a reliable benefit across test and external cohorts. Differences between patient populations may explain some decline, which is exactly why local calibration and prospective evaluation matter. The authors describe silent prospective validation in more than two thousand patients, another usability study, and a planned pragmatic randomized trial before deployment. The result is promising decision support, not autonomous clinical authority.

7 min
Six protein biomarker dials converge on an experimental molecule above a lung scan while an unfinished trial path continues into shadow.
Social good & healthGlobal+2 clusters06

An AI-discovered lung drug shifted six aging clocks, not human lifespan

An experimental drug developed with AI has produced a result that is scientifically interesting and extremely easy to oversell. Rentosertib was designed for idiopathic pulmonary fibrosis, a progressive scarring disease of the lungs. Its target was identified with AI and its molecule was generated through an AI-driven discovery platform. Researchers analyzed protein data from 42 patients in a 12-week phase 2a trial and applied six independently developed proteomic aging clocks. All six estimated a reduction in predicted biological age among treated patients. Earlier trial results also showed a promising dose-related improvement in forced vital capacity, an important lung-function measure. Agreement across multiple clocks makes the signal less likely to be an artifact of one aging model. It does not prove that the drug extends life, reverses aging throughout the body, or is safe and effective as a longevity treatment. The cohort was small, the follow-up was short, the participants had a serious age-related disease, and improving inflammation or fibrosis can change proteins used by aging clocks. The Nature Biotechnology paper also discloses that several authors work for the company developing the drug and that its company leader is an author. The responsible interpretation is neither miracle nor dismissal. This is a hypothesis-generating biomarker result attached to a candidate that has advanced in clinical development. Larger, longer, independently scrutinized trials should prespecify aging endpoints and connect them with functional outcomes, safety, disease progression, and eventually survival. AI accelerated the discovery path. Biology still decides whether the claim survives.

5 min
A cinematic museum-at-night installation shows an automated factory of occupations stopping at a velvet rope around a warm human care chair and joined hands.
Work & marketsGlobal+5 clusters07

A technology optimist asks society to reserve some work for humans

A New York Times report and a new long-form essay mark a sharp change in the tone of one of technology's best-known optimists. The warning focuses on three overlapping risks: AI-enabled security threats such as hacking, biological misuse, and fraud; job destruction across cognitive and physical work; and harm to children's learning and human relationships. The argument is not that AI lacks benefits. It is that governments have no adequate architecture for a transition that could move faster than earlier industrial changes. One proposal is a Human Reserved domain: jobs or tasks society deliberately protects for people even when AI or robots could do them, with care work as the clearest example. The author also calls for national coordination across employment, education, taxation, health, security, and other systems, plus international cooperation. These are proposals, not settled policy, and they raise difficult enforcement and distribution questions. Their importance is the principle that technical capability does not automatically authorize replacement.

5 min
A precise national-policy dossier shows AI benefits passing through signed safety, worker-support, and human-control checkpoints before a scale gate opens.
Law & informationSingapore+4 clusters08

Singapore puts human control at the center of national AI adoption

Singapore’s 2026 National Day Rally framed AI adoption as a national bargain rather than an unrestricted technology race. The prime minister highlighted AI agents for small businesses, personalized exercise plans, breast-cancer screening support, genomics, and autonomous-vehicle trials. He also said adoption should not run ahead of the country’s ability to retrain and support affected workers, that autonomous vehicles should scale only after safety is proven, and that people must remain in control as capable agents create harder-to-predict risks. The speech committed Singapore to practical safeguards at home and coalitions for international rules, while stopping short of specifying every enforcement mechanism or timetable. The value of the approach is its sequence: prove the system, govern the risk, support the people disrupted, then scale. That standard now needs measurable implementation through named regulators, published stop conditions, worker outcomes, incident disclosure, and public evidence that human control is operational rather than ceremonial.

5 min
A wall of 1,357 medical-device approval tiles narrows to three illuminated patient-outcome records beside an empty hospital evidence chart.
Social good & healthUnited States · Global implications+3 clusters09

Only three of 1,357 FDA-authorized AI medical devices were evaluated on patient outcomes

A PLOS Digital Health evidence census linked the FDA's 1,357 authorized AI and machine-learning medical devices through December 5, 2025 to prospective trials and publications. Thirty-four devices were linked to registered prospective trials, 12 had posted results, 12 had peer-reviewed publications, and only three evaluated patient-centered outcomes such as mortality, morbidity, or readmission. The review does not show that the remaining devices are ineffective; it shows that authorization and benchmark performance rarely answer the outcome question patients care about most. With 78 percent of the devices concentrated in radiology and vulnerable populations often excluded from studies, the validation gap can travel through hospitals and across countries long before durable benefit or equitable performance is known.

5 min
A clinical waveform and reinforcement-learning decision tree ending at an evidence gap.
Cognition & learningGlobal+2 clusters10

Tang et al., “Reinforcement learning for treatment decision-making in sepsis: a scoping review”

Reviewing 72 studies of reinforcement-learning systems for sepsis treatment, the authors found that every study was retrospective, 58 studies—80.6%—relied on the same MIMIC critical-care database, and only 10 used private datasets. Although many papers claimed that AI-derived treatment policies outperformed clinicians, variation in how patient states, treatment actions, rewards, and counterfactual outcomes were defined made those comparisons difficult to validate.

2 min